Published in Cell Discov on November 15, 2016
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife (2017) 0.75
Overview of Cancer Stem Cells and Stemness for Community Oncologists. Target Oncol (2017) 0.75
Transgenic overexpression of NanogP8 in the mouse prostate is insufficient to initiate tumorigenesis but weakly promotes tumor development in the Hi-Myc mouse model. Oncotarget (2017) 0.75
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol (2010) 16.72
MEME: discovering and analyzing DNA and protein sequence motifs. Nucleic Acids Res (2006) 15.32
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell (2011) 2.83
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell (2014) 2.60
Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells (2009) 2.59
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell (2012) 2.49
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 2.22
NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 2.01
WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res (2009) 1.89
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res (2011) 1.89
Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J (2010) 1.73
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nat Commun (2016) 1.65
Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol (2011) 1.56
NANOGP8 is a retrogene expressed in cancers. FEBS J (2006) 1.40
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol (2011) 1.20
NANOG modulates stemness in human colorectal cancer. Oncogene (2012) 1.19
Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun (2014) 1.08
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A (2016) 1.08
Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther (2013) 1.06
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet (2015) 1.04
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget (2015) 1.00
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00
Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. Stem Cells (2015) 0.96
NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol Endocrinol (2014) 0.96
Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions. Stem Cells (2015) 0.91
In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals. Cell Cycle (2013) 0.89
Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia. Nat Commun (2014) 0.89
CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget (2015) 0.85
Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer. Oncogene (2013) 0.84
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate (2014) 0.83
Nanog1 in NTERA-2 and recombinant NanogP8 from somatic cancer cells adopt multiple protein conformations and migrate at multiple M.W species. PLoS One (2014) 0.81
TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice. Gastroenterology (2015) 0.80
Regulation of NANOG in cancer cells. Mol Carcinog (2015) 0.79
Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. Clin Cancer Res (2016) 0.79
Pluripotency factor Nanog is tumorigenic by deregulating DNA damage response in somatic cells. Oncogene (2015) 0.77